TORONTO, ON, May 7, 2026
Cardiol Therapeutics Inc. announced that results from its Phase II MAvERIC study evaluating CardiolRx™ in patients with recurrent pericarditis have been accepted for publication in the Journal of the American Heart Association (JAHA), marking an important milestone for the company’s late-stage cardiovascular drug development program. The peer-reviewed publication highlights significant reductions in pericarditis pain and inflammation and further validates the ongoing pivotal Phase III MAVERIC trial, which has already surpassed 75% enrollment.
Phase II Data Strengthens CardiolRx Clinical Potential
The accepted publication demonstrated that treatment with CardiolRx™ was associated with rapid and sustained improvement in patients suffering from recurrent pericarditis, an inflammatory heart disease characterized by debilitating chest pain, fatigue, and repeated hospitalizations. According to the study findings, patients experienced a substantial reduction in annual pericarditis episodes alongside a favorable safety and tolerability profile. These findings are considered highly significant because current treatment approaches often rely on long-term immunosuppressive therapies, corticosteroids, and injectable biologics that may lead to dependency and severe adverse effects.
Cardiol Therapeutics stated that the publication provides independent scientific validation of the company’s clinical findings and supports the potential of CardiolRx™ as a differentiated non-immunosuppressive therapy for recurrent pericarditis. The company believes the data reinforces the broader opportunity for CardiolRx™ to address major unmet medical needs in inflammation-driven cardiovascular diseases.
Ongoing Phase III MAVERIC Trial Advances
Advertisement
The ongoing Phase III MAVERIC trial is a randomized, double-blind, placebo-controlled pivotal study evaluating CardiolRx™ for the prevention of recurrent pericarditis episodes. The trial recently crossed the 75% enrollment milestone, signaling continued momentum in the company’s regulatory and clinical development strategy.
CardiolRx™ has already received FDA Orphan Drug Designation for the treatment of pericarditis, including recurrent pericarditis, further strengthening the program’s regulatory position in the United States. The therapy works by modulating inflammasome pathway activation, an intracellular process linked to inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.
The publication acceptance also supports broader scientific understanding of anti-inflammatory therapies in cardiovascular disease management. Researchers and clinicians increasingly view inflammation as a critical therapeutic target in heart disease, particularly in conditions involving fibrosis and chronic cardiac tissue damage.
Recurrent Pericarditis Remains a Significant Unmet Need
Recurrent pericarditis continues to represent a major healthcare burden globally. The condition often develops following viral infections and can lead to repeated inflammatory episodes over several years. Symptoms such as severe chest pain, fatigue, shortness of breath, and physical limitations significantly reduce patient quality of life and frequently result in emergency department visits and hospitalizations.
According to Cardiol Therapeutics, approximately 40,000 patients in the United States experience at least one recurrence annually, while nearly 60% of patients with multiple recurrences suffer for more than two years. One-third of patients remain affected even after five years, underscoring the urgent need for safer long-term treatment options.
The company is also advancing additional cardiovascular programs, including CRD-38, a novel subcutaneous formulation intended for inflammatory heart disease and heart failure treatment. These programs position Cardiol Therapeutics as an emerging player in the development of targeted anti-inflammatory therapies for cardiovascular medicine.
Source: Cardiol Therapeutics press release
